Psoriatic Arthritis News

Psoriasis has a substantial psychological burden that affects quality of life for many patients, according to a presentation at the European Academy of Dermatology and Venereology virtual congress.

In a real-world cohort of more than 2,000 U.S. patients with psoriatic arthritis, most had multidomain presentations, which were associated with worse disease activity, quality of life and work productivity, according to data published in The Journal of Rheumatology.

Short interruptions in face-to-face rheumatology visits due to COVID-19 considerations resulted in no major negative effects for patients with inflammatory arthritis, according to findings published in Annals of the Rheumatic Diseases.

The percentage of adult arthritis visits to office-based physicians increased significantly during 2006-2015, with the percentage of visits where opioids were prescribed also increasing during that time, according to data.

Latent tuberculosis infection was an uncommon adverse event after treatment with secukinumab for chronic systemic inflammatory conditions, according to a study published in JAMA Dermatology.

Healio Psoriatic Disease, the first publication focused on informing health care professionals about the burden of psoriatic disease and the understanding of psoriasis as a systemic disease, has named Joel M. Gelfand, MD, MSCE, as its Chief Medical Editor.

Novel therapies are providing hope for more targeted therapy options in managing the myriad manifestations of psoriatic arthritis, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

Psoriatic arthritis and gout often present with similar symptoms and radiological signs, an overlap that may be more significant when these diseases occur concomitantly, noted a presenter at the 2020 Congress of Clinical Rheumatology-West.

TNF inhibitors and methotrexate produced similar reductions in HbA1c among patients with psoriatic arthritis, rheumatoid arthritis or ankylosing spondylitis who also have diabetes, according to data published in BMC Rheumatology.

Treatment of psoriatic conditions or Crohn’s disease with ustekinumab was associated with severe cardiovascular events in certain high-risk patients, according to a study.